Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Pain. 2016 May;157(5):1122–1131. doi: 10.1097/j.pain.0000000000000489

Table 5.

Risk Factors Associated with Pre-RT, Post-RT and RT-Associated Clinically-Relevant Pain

Variable Comparisons OR (95%CI) P1
Pre-RT Pain (Yes vs. No)2
Race/ethnicity AA vs. NHW 3.87 (0.82–18.44) 0.089
HW vs. NHW 5.06 (1.17–21.83) 0.030
BMI (kg/m2) ≥30 vs. <30 2.46 (1.34–4.50) 0.004
Taxane + Trastuzumab Either vs. None/other chemotherapy 1.34 (0.69–2.58) 0.387
Both vs. None/other chemotherapy 2.43 (0.88–6.73) 0.088
Axillary surgery ALND vs. SLNB or None 1.53 (0.80–2.92) 0.198
Post-RT Pain (Yes vs. No)2
Race/ethnicity AA vs. NHW 3.75 (1.19–11.85) 0.024
HW vs. NHW 3.14 (1.08–9.11) 0.036
Age (yrs.) <50 vs. ≥50 3.09 (1.57–6.10) 0.001
BMI (kg/m2) ≥30 vs. <30 1.26 (0.69–2.29) 0.460
# Comorbidities3 1 vs. 0 1.17 (0.59–2.33) 0.661
2 vs. 0 3.04 (1.31–3.08) 0.010
≥3 vs. 0 5.68 (1.60–20.18) 0.007
RT Type Conventional vs. Hypofractionation 1.49 (0.58–3.82) 0.408
V105 (cc) ≥241.7 vs. <241.7 1.80 (1.00–3.23) 0.050
Pre-RT pain score ≥ 4 vs. <4 4.65 (2.30–9.38) <0.0001
RT-Associated Pain (Yes vs. No)4
Race/ethnicity AA vs. NHW 3.27 (1.09–9.82) 0.034
HW vs. NHW 2.08 (0.75–5.82) 0.162
Age (yrs.) <50 vs. ≥50 2.44 (1.24–4.79) 0.010
# Comorbidities3 1 vs. 0 1.18 (0.58–2.43) 0.648
2 vs. 0 3.06 (1.32–7.08) 0.009
≥3 vs. 0 4.61 (1.49–14.25) 0.008
RT Type Conventional vs. Hypofractionation 2.41 (0.80–7.19) 0.117
1

P values from multi-variable logistic regression. Significant findings were in bold.

2

Pain score <4 and ≥ 4 was considered no and yes for pain, respectively.

3

Sum of 11 comorbidity conditions: diabetes, hypertension, heart disease, lung disease, thyroid disease, liver cirrhosis, stroke, chronic bronchitis, hepatitis, tuberculosis, and other.

4

RT-associated pain was based on the change from no for pre-RT to yes for post-RT pain.